Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double blind, randomized, placebo controlled, cross-over, Lybridos dose finding study to validate the predictive power of the diagnostic model for Lybrido and Lybridos efficacy and to identify and evaluate additional psychometric and biological markers which increase the predictive power of the diagnostic model, in women with hypoactive sexual desire disorder with or without sexual arousal disorder and/or female orgasmic disorder or SSRI induced sexual dysfunction, in the domestic situation.

Trial Profile

A double blind, randomized, placebo controlled, cross-over, Lybridos dose finding study to validate the predictive power of the diagnostic model for Lybrido and Lybridos efficacy and to identify and evaluate additional psychometric and biological markers which increase the predictive power of the diagnostic model, in women with hypoactive sexual desire disorder with or without sexual arousal disorder and/or female orgasmic disorder or SSRI induced sexual dysfunction, in the domestic situation.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buspirone/testosterone (Primary) ; Sildenafil/testosterone (Primary)
  • Indications Decreased libido; Female sexual dysfunction
  • Focus Therapeutic Use
  • Acronyms @home
  • Sponsors Companion Diagnostics BV
  • Most Recent Events

    • 08 Apr 2014 New source identified and integrated (Netherlands Trial Register; NTR4426)
    • 08 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top